

Hepatology and Liver Transplantation Webinar Key Points and Bibliographic Reference

Talk Title	Speaker Name	Key Points	Key Takeaways	Bibliographic Information
Liver Transplantation: Before, During, and After	Avash Kalra, MD	<ol style="list-style-type: none"> 1) Identify clinical decompensations in patients with liver disease. 2) Review the indication for liver transplantation. 3) Understand the use of the MELD score. 4) Identify an approach to alcohol use and sobriety in the setting of a potential liver transplant evaluation. 5) Develop an understanding of the multidisciplinary care involved with liver transplantation. 	<ol style="list-style-type: none"> 1) Consider screening for NAFLD in high-risk populations. 2) Identify clinical decompensations in patients with chronic liver disease 3) Prompt early referral for liver transplantation evaluation if appropriate. 3) The MELD score predicts waiting list mortality and continues to evolve. 4) There is no six-month rule of sobriety for patients with alcohol associated liver disease. Demonstration of insight and engagement in sobriety efforts (and support!) are critical. 5) It is appropriate to prepare patients for the multidisciplinary nature of a transplant evaluation. 6) Living donor liver transplant frees patients from the wait list with excellent outcomes. 	<ol style="list-style-type: none"> 2) D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. <i>J Hepatol.</i> 2006; 44:217-31 3) Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. <i>Liver Int.</i> 2012;32:72-94. 4) Vergara M, et al. <i>Liver Int</i> 2013;33:828. 5) Wong et al. <i>JAMA Netw Open.</i> 2020. 6) Chalasani N et al. The Diagnosis and Management of NAFLD:Practice Guidance From the AASLD. <i>Hepatology</i> 2018 7) Ando Y et al. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. <i>Clinical Liver Disease</i> 2021 8) Chalasani N et al. The Diagnosis and Management of NAFLD:Practice Guidance From the AASLD. <i>Hepatology</i> 2018 9) Vilar-Gomez et al Weight Loss Through Lifestyle Modification Significantly Reduces Features of NASH. <i>Gastro</i> 2015 10) Harrison SA et al. Orlistat for overweight subjects with NASH: A randomized, prospective trial. <i>Hepatology</i> 2009 11) Kim et al. <i>NEJM</i> 2008. 12) Wiesner et al. <i>Gastroenterology</i> 2003. 13) Merion RM et al. <i>Am J Transplant</i> 2005. 14) Somsouk, et al. <i>Liver Transpl</i> 2011. 15) Mazzaferro et.al. <i>NEJM</i> 1996. 16) Yao FY et al. <i>Hepatology</i> 2015. 17) https://oncohemakey.com/cancer-of-the-liver/ 18) Sharpton et al. <i>Transplantation.</i> 2014. 19) 2017 Annual Data Report. <i>SRTR.</i> 20) OPTN. http://optn.transplant.hrsa.gov. Accessed 3/1/2019. 21) Martin et al. <i>AASLD Practice Guideline</i> 2003. 22) Leithead et al. <i>Liver Transpl</i> 2008 23) Tsiaousi et al. <i>J Gastroenterol Hepatol</i> 2008